Idelalisib, a δ-selective PI3K inhibitor approved for relapsed chronic lymphocytic leukemia [30], was used as a positive control and showed strong activity against p110δ driven cells (IC50 = 32 nM). This evidence concerns the gene PIK3CB and B-cell chronic lymphocytic leukemia.